Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
about
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticalsOverexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progressionHead and neck cancer: metronomic chemotherapyUnderstanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease ProgressionmiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivoTargeted treatment for chronic lymphocytic leukemia.Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapyReprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria and protect against necrosis in experimental pancreatitisIn vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castrationMechanisms and insights into drug resistance in cancerAmphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interactionMir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancerTumour dormancy and clinical implications in breast cancer.Road for understanding cancer stem cells: model cell lines.Cancer stem cells: implications for the progression and treatment of metastatic disease.Cancer treatment: the combination of vaccination with other therapies.Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effectsA phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.BCL2 as a Subtype-Specific Prognostic Marker for Breast CancerQuantification of endothelial cell-targeted anti-Bcl-2 therapy and its suppression of tumor growth and vascularization.IL-6/STAT3/TWIST inhibition reverses ionizing radiation-induced EMT and radioresistance in esophageal squamous carcinoma.Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Combinatorial strategies employing nutraceuticals for cancer development.Organellar dysfunction in the pathogenesis of pancreatitis.Cancer stem cells, tumor dormancy, and metastasis.Salivary gland cancer stem cells.Chemical biology of compounds obtained from screening using disease models.miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.Hypoxia-regulated p53 and its effect on radiosensitivity in cancer cells.Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells.Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cellsIncrease of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Conference report--at the forefront of cancer research: preclinical data highlights of annual meeting of the 95th American Association for Cancer Research; March 27-31, 2004; Orlando, Florida.Targeting breast cancer stem cells
P2860
Q24631327-974A8DCC-6A2F-4097-842E-72B55AB59D6FQ24813774-8775B1A0-C992-4606-B396-21B2A9B43318Q26784018-90082938-927F-47B7-9A58-6EDE0626E5DDQ26829949-2A40B2AD-AAC8-4D11-BFAA-927C723D99E4Q34160439-61206BC7-AF5C-462A-AA25-C0713276578BQ35387996-A64BCFA4-E613-4753-AD45-F754C7A39417Q35599741-EDBF1BCD-3F1A-422C-B147-BA2A21BE4B34Q35652502-B84587D7-22BF-4C69-B2BF-590BCE1D2B41Q35799094-EA23478B-523A-4414-8B96-2415A3841484Q35983626-6DBD6DFD-75CB-43D5-9359-24F9093313CFQ36259619-EBD28151-1B97-453B-8BE5-9A73F528F449Q36682301-26D382F4-9BDD-460B-BB54-037D5D310937Q36718859-BD69CC89-E717-41F8-B33F-BD97911E2561Q36853421-92A712A0-F264-4686-8B14-684AA33212EDQ36863179-B8CAE1C2-BBE7-44F7-9446-C441BBC51464Q37012033-BB283AD1-3CC8-492B-9B11-25FE38D4E852Q37053174-41E11A9A-803D-4152-A38D-8952AD97AAABQ37089001-EA512CF5-FB6E-4BE5-A5F6-A3541D2A20DCQ37109324-FEA7892D-E545-481F-87B1-0F72E83EE82CQ37284056-F0521761-2F1B-4C42-8640-FA40DADA681FQ37316599-6E56DB1B-F219-42F9-AC94-7E4E467EA8BBQ37419813-8A50A11B-C5C4-40D7-AC56-6B582FF8E697Q37706895-2D88092E-0734-4D20-910D-07BBAA85CDE5Q37713757-5CD24FB6-9563-4B03-A70E-30C70F183D61Q37838167-338442F5-5205-4253-83B5-332DDDCD2211Q37906730-EE2E8F59-A2B8-4E9D-81FF-C0BCA38CE5F8Q37915531-7DAB87A1-EB1D-409A-A09C-F1FB52295B6EQ38056500-7ACF9420-45B6-47A8-9411-74738D3F6F6FQ38117949-728A123B-9673-4422-8F1D-E7EBE5A7E368Q38547710-3AC93F1D-355C-4A4E-969C-301697A7849CQ39459142-3CCAA23B-A73E-44DD-9289-F9DEF7095ACBQ40125495-2D56DD06-B6E9-4327-B070-9EC66191C311Q40125939-892C1DD4-D6F8-4001-8E9A-DA0B88A9FBDBQ40340077-E75D9B16-5E41-4309-8FFC-637FEAC33FB9Q40485500-C764119E-9A33-4A4F-8508-0683E06D7FD0Q41972376-1438868E-F4F3-4672-94CD-AC822D61B58AQ42324488-BCF50359-2B28-4D13-86EF-66BC3001030AQ42700663-A436DC9C-E371-47C8-8E0A-845D7BF47E0DQ50746648-516260B3-1C22-40D7-9BEA-2C24C159B2ECQ57139325-C7C99AF8-67CD-44E8-BB97-82199F747739
P2860
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@ast
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@en
type
label
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@ast
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@en
prefLabel
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@ast
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@en
P2093
P1433
P1476
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
@en
P2093
Dajun Yang
Marc E Lippman
Shaomeng Wang
P304
P356
10.1053/J.SEMINONCOL.2003.08.015
P433
5 Suppl 16
P577
2003-10-01T00:00:00Z